{
  "abstract": "The prevalence of end-stage acute or chronic liver disease (ESLD) continues to increase worldwide, largely driven by alcohol abuse, viral hepatitis and metabolic dysfunction-associated steatotic liver disease. These conditions can ultimately lead to loss of hepatic function and architecture, progressing to advanced stages such as cirrhosis and hepatocellular carcinoma, in which the regenerative capacity of the liver is exhausted and the organ is unable to recover its essential function. At this stage, liver transplantation remains the only effective therapy for most ESLDs.1 However, during transplantation or major hepatic resection, hepatic ischaemia–reperfusion injury (HIRI) can occur, leading to early allograft dysfunction and postoperative complications, including graft rejection. Despite decades of investigation, no effective solutions for HIRI have yet been established. This problem is particularly relevant in elderly patients, who constitute an increasing proportion of surgical candidates and exhibit heightened susceptibility to ischaemic stress due to age-related changes in hepatic resistance.2 Particularly, chronic inflammation is common in the elderly population of Western societies, especially when a significant portion of the adult population has BMIs at/above 25 and tends to be sedentary.3 In this issue, the concept of ‘inflammaging’—a chronic, low-grade inflammatory state that accompanies ageing—has gained attention as a determinant of tissue resilience and immune dysfunction. Understanding how inflammaging affects hepatic ischaemia–reperfusion responses may, therefore, be key to improving outcomes in older surgical candidates.4",
  "authors": [
    {
      "affiliations": [
        "Health Research Institute Aragón, Zaragoza, Aragon, Spain"
      ],
      "name": "Javier Martínez-García"
    },
    {
      "affiliations": [
        "Department of Biochemistry, University of Nebraska, Lincoln Lincoln, Nebraska, USA"
      ],
      "name": "Edward Harris"
    },
    {
      "affiliations": [
        "Health Research Institute Aragón, Zaragoza, Aragon, Spain",
        "Carlos III University of Madrid",
        "CIBERehd",
        "ARAID Foundation, Madrid and Zaragoza, Spain"
      ],
      "name": "Pedro M Baptista"
    }
  ],
  "title": "Targeting interleukin signalling in liver disease: a new frontier for therapeutic blockade and immunomodulation",
  "uid": "b906dc8a-b7e0-5984-9580-ad1bbf3a01f3"
}